NEW YORK (TheStreet) -- The S&P 500 sold off near the end of Tuesday's trading session, closing lower by 0.64%.
On CNBC's "Fast Money" TV show, Guy Adami, managing director of stockmonster.com, said Tuesday's housing data were good but the bond market still refused to selloff. He reasoned that Treasury yields are likely headed lower while the S&P 500 could skid into the end of month, possibly falling to 1,860.
Brian Kelly, founder of Brian Kelly Capital, said he was surprised the stock market sold off following such positive results from Tuesday's new-home sales. He took profits in his long S&P 500 position.
Dan Nathan, co-founder and editor of riskreversal.com, said the S&P 500 is unlikely to decline to 1,860. He added that bonds have done well because it's one of the few safe haven assets left for investors to buy.
Karen Finerman, president of Metropolitan Capital Advisors, said she is more inclined to buy volatility at current levels, than to sell it, despite the CBOE Volatility Index I:VIX rallying more than 10%.
Nathan and Finerman said there needs to be more positive data on the housing market to truly confirm that it is improving. Nathan called the housing market a "mixed bag" at the moment.
Robyn Karnauska, biotechnology analyst at Deutsche Bank, was a guest on the show. She is not a seller of Vertex Pharmaceuticals (VRTX) - Get Vertex Pharmaceuticals Incorporated Report and still has a buy rating on the stock despite its jump by 40% on Tuesday. The stock popped on positive Phase 3 trial results for its cystic fibrosis treatment. The stock has more upside as the company can afford to raise prices. She added that Pharmacyclics (PCYC) could double in the next 12 months.
Kelly said the iShares Nasdaq Biotechnology ETF (IBB) - Get iShares NASDAQ Biotechnology ETF Report is a good way for investors who don't have a lot of knowledge in the biotech space to gain broad exposure to the industry.
Finerman agreed, adding the exchange-traded fund will provide investors with less volatility than they would have by simply owning individual biotech stocks.
Adami continues to like Gilead Sciences (GILD) - Get Gilead Sciences, Inc. (GILD) Report and Celgene (CELG) - Get Celgene Corporation Report. He said Bristol-Myers Squibb (BMY) - Get Bristol-Myers Squibb Company Report has an unattractive valuation. Kelly said investors can buy BMY with a stop-loss near $47.50.
Elizabeth Arden (RDEN) is trying to do the right things but is not attractive to investors at current levels, according to Finerman.
"Last quarter was spectacular," Adami said about Facebook (FB) - Get Facebook, Inc. Class A Report, " I think it goes higher from here." Nathan said FB shares continue to trade well but eventually the growth will slow.
Tom Werner, chairman, president and CEO of SunPower (SPWR) - Get SunPower Corporation Report, said the company plans on providing residential customers with lithium ion battery storage options. That means customers will be able to store additional electricity generated from solar power energy and use it whenever they want. He added that the company's strong balance sheet makes SunPower rather flexible when looking at expanding its business.
Adami said investors can stay long shares of SPWR with a stop-loss near $40. Nathan said investors could stay long SPWR but with a stop-loss near $35.
Kelly pointed out that investors can buy silver, which is needed by solar panel providers. As demand for solar increases, so will demand for silver, he reasoned.
Finerman is a buyer of SunEdison (SUNE) .
Steven Berkowitz, CEO of Move, Inc. (MOVE) , noted housing sales got off to a sluggish start in 2014 but finally seem to be picking up, based on the increased traffic he sees for his company's Web site, realtor.com. He argued his company's listings are the most accurate because they are updated every 15 minutes.
Finerman is "taking a pass" on Dr Pepper Snapple Group (DPS) , which fell 1% on Tuesday.
Web.com Group (WWWW) plunged 20%. Nathan said the company may become a takeover candidate but he suggested letting the stock settle down for a few days before considering a long position.
Mark Daiss and Paul Montoy-Wilson, product managers for Aviate, a recent Yahoo! (YHOO) acquisition, were guests on the show. They said Aviate is a product for Android devices that allow users' smartphones to become "simpler and smarter" to use. It organizes users' apps and can automatically brings the most relevant content right to the home screen, the most commonly visited place on users' smartphones. For now the company is focused on user experience, not generating revenue.
Nathan questioned how Yahoo! will be able to successfully implement all of its different, recent acquisitions.
Adami said shares of Yahoo! seem to have support near $33. However, the company needs to do well when it report earnings on July 22 or CEO Marissa Mayer may find herself on the hot seat.
For their final trades, Nathan is a seller of the Energy Select Sector SPDR ETF (XLE) - Get Energy Select Sector SPDR Fund Report and Kelly is a buyer of Control4 (CTRL) - Get Control4 Corporation Report. Adami is buying the iShares 20+ Year Treasury Bond ETF (TLT) - Get iShares 20+ Year Treasury Bond ETF Report and Finerman is looking for protection in the form of long SPDR S&P 500 Trust ETF (SPY) - Get SPDR S&P 500 ETF Trust Report put options.
-- Written by Bret Kenwell in Petoskey, Mich.
Bret Kenwell currently writes, blogs and also contributes to Robert Weinstein's Weekly Options Newsletter.